Genmab A-S

Cerrado

1,700.5 -1.59

Resumen

Variación precio

24h

Actual

Mínimo

1652.5

Máximo

1728

Métricas clave

By Trading Economics

Ingresos

21M

52M

Ventas

-184M

881M

P/B

Media del Sector

19.446

50.958

BPA

8.48

Margen de beneficios

5.915

Empleados

3,088

EBITDA

-30M

215M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-1.49% downside

Dividendos

By Acuity

Próximas Ganancias

6 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-2.5B

102B

Apertura anterior

1702.09

Cierre anterior

1700.5

Genmab A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 jun 2026, 23:56 UTC

ETF Constituents
Correlated Moves
Macro News

The Consumer Discretionary Select Sector SPDR Fund declined after the U.S. core PCE price index rose, exceeding the Federal Reserve's target and impacting sentiment.

25 jun 2026, 23:56 UTC

Gilead Sciences shares moved higher in after-market hours, despite earlier declines during regular trading amid mixed U.S. market performance influenced by economic data.

25 jun 2026, 23:52 UTC

U.S. equity markets show mixed results amid inflation concerns and stronger-than-expected GDP growth, while the dollar strengthens as Treasury yields drive forex dynamics.

25 jun 2026, 23:52 UTC

European equity markets rise on strong tech earnings, while UK retail struggles and France sees improved consumer confidence amidst mixed economic signals.

25 jun 2026, 23:52 UTC

Global markets show mixed performance as U.S. tech stocks lag despite strong job data and GDP growth, while Japan's Nikkei rises on positive earnings.

25 jun 2026, 23:52 UTC

Mixed Asia equity markets as Japan's Nikkei rises 4.3% on strong tech earnings, while U.S. jobless claims drop and GDP growth is revised up, amid persistent inflation concerns.

25 jun 2026, 23:52 UTC

Macro News

The Nikkei 225 Index is lower in after-market hours amid yen weakness and rising geopolitical tensions affecting investor sentiment.

25 jun 2026, 23:51 UTC

Incyte Corp shares are higher in after-market hours, recovering from an earlier session low. Broader market performance remains mixed amid varying tech stock results.

25 jun 2026, 23:51 UTC

Monster Beverage Corp. shares are lower in after-market trading, continuing a decline since Thursday's close, despite remaining above the 20-day moving average.

25 jun 2026, 23:51 UTC

Electronic Arts Inc. shares are lower in after-market trading amid notable weakness in the Interactive Home Entertainment sub-sector. No specific news was identified.

25 jun 2026, 23:51 UTC

Charter Communications Inc shares are higher in after-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

25 jun 2026, 23:51 UTC

Market Anticipates Positive Job Growth in Upcoming ADP Employment Report Amid Optimistic Labor Market Sentiment and Inflation Concerns.

25 jun 2026, 23:51 UTC

American Airlines shares are lower in after-market hours, with no specific news identified. The broader market showed mixed performance following Thursday's close.

25 jun 2026, 23:51 UTC

Correlated Moves
Macro News

The S&P 500 Index is lower today amid a securities fraud lawsuit against Zillow and rising geopolitical tensions affecting market sentiment.

25 jun 2026, 23:51 UTC

Workday Inc shares are higher in after-market trading, driven by gains in the Application Software sub-sector. The stock has recovered from earlier lows.

25 jun 2026, 23:51 UTC

Correlated Moves
Social Media

Applied Materials shares are higher in after-market hours following Citi's price target increase to 710 and positive sentiment in the semiconductor equipment sector.

25 jun 2026, 23:51 UTC

News

Crude oil prices rise amid escalating Middle East tensions after a projectile strike near Oman. The United States Oil Fund LP is slightly higher after hours.

25 jun 2026, 23:51 UTC

ETF Constituents

iShares Biotechnology ETF is higher in after-market trading, supported by gains from Vertex Pharmaceuticals, Gilead Sciences, and Incyte Corporation among others.

25 jun 2026, 23:51 UTC

T-Mobile US Inc shares are higher in after-market hours, showing unusual strength amid mixed broader market performance with no specific news identified.

25 jun 2026, 23:51 UTC

Social Media
Correlated Moves
News

Qualcomm is in talks to acquire Modular for $4 billion. Shares are trading lower after the company's optimistic revenue targets and Investor Day updates.

25 jun 2026, 23:51 UTC

Social Media
News

Micron Technology Inc. shares fell in after-market trading despite a 350% year-over-year revenue increase, amid broader tech sector weakness.

25 jun 2026, 23:51 UTC

The EUR/HUF is lower in Thursday's session amid ongoing market volatility. The currency pair briefly gained before declining without a specific identified driver.

25 jun 2026, 23:51 UTC

Correlated Moves

Ethereum is trading lower, continuing a four-session decline amid significant volatility. It remains under pressure, well below its 20-day moving average.

25 jun 2026, 23:51 UTC

Social Media
Correlated Moves

Broadcom Inc. shares were roughly flat in after-market trading, continuing a trend of decline this month, contrasting with gains among other large S&P 500 stocks.

25 jun 2026, 23:51 UTC

NetEase Inc shares are higher in after-market hours following Thursday's close, despite remaining below the 20-day moving average. No specific news was identified.

25 jun 2026, 23:46 UTC

Correlated Moves

Vanguard Total International Bond ETF trades near unchanged after hours, reflecting stable performance amid slight declines in the US 10Y Treasury Bond.

25 jun 2026, 23:46 UTC

Correlated Moves

iShares TIPS Bond ETF remains flat in after-hours trading, reflecting stability amid a slight increase in the iShares iBoxx $ High Yield Corporate Bond ETF.

25 jun 2026, 23:46 UTC

ETF Constituents
Correlated Moves

Health Care Select Sector SPDR Fund declines in after-market hours, reflecting broader market trends. Key holdings Zoetis and Baxter contribute negatively to performance.

25 jun 2026, 23:46 UTC

SPDR Gold Shares are trading lower in after-market hours, remaining below the 20-day moving average and near the lower end of its one-month trading range.

25 jun 2026, 23:46 UTC

PayPal Holdings Inc shares are higher in after-market trading, influenced by strong earnings from Micron Technology amid a mixed tech sector performance.

Comparación entre iguales

Cambio de precio

Genmab A-S previsión

Precio Objetivo

By TipRanks

-1.49% descenso

Estimación a 12 Meses

Media 2,493.35 DKK  -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genmab A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

3

Comprar

2

Mantener

2

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.